The possible advantage of hybrid closed-loop therapy (i.e., artificial pancreas) over sensor-augmented pump therapy in very young children with type 1 diabetes is unclear. In this multicenter, ...
The US Food and Drug Administration (FDA) has cleared the Tidepool Loop, a mobile application for use with compatible continuous glucose monitors (CGMs) and insulin pumps to enable automated insulin ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する